within Pharmacolibrary.Drugs.ATC.B;

model B01AC22
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.79,
    Cl             = 63.1 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,
    adminCount     = 1,
    Vd             = 0.0442,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.021666666666666667,
    Tlag           = 12.0
  );

  annotation(Documentation(
    info ="<html><body><p>Prasugrel is an oral antiplatelet agent used for the prevention of atherothrombotic events in patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI). It is a thienopyridine class inhibitor of the P2Y12 ADP platelet receptor. Prasugrel is approved and used in clinical practice for patients at risk of thrombotic cardiovascular events.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult subjects following single oral administration of prasugrel 10 mg.</p><h4>References</h4><ol><li><p>Gelbenegger, G, &amp; Jilma, B (2022). Clinical pharmacology of antiplatelet drugs. <i>Expert review of clinical pharmacology</i> 15(10) 1177–1197. DOI:<a href=&quot;https://doi.org/10.1080/17512433.2022.2121702&quot;>10.1080/17512433.2022.2121702</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36065676/&quot;>https://pubmed.ncbi.nlm.nih.gov/36065676</a></p></li><li><p>MacDougall, C, et al., &amp; Louie, J (2022). Systematic review of drug-drug interactions between rifamycins and anticoagulant and antiplatelet agents and considerations for management. <i>Pharmacotherapy</i> 42(4) 343–361. DOI:<a href=&quot;https://doi.org/10.1002/phar.2672&quot;>10.1002/phar.2672</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35152432/&quot;>https://pubmed.ncbi.nlm.nih.gov/35152432</a></p></li><li><p>Abrignani, MG, et al., &amp; Abrignani, V (2023). Proton pump inhibitors and gastroprotection in patients treated with antithrombotic drugs: A cardiologic point of view. <i>World journal of cardiology</i> 15(8) 375–394. DOI:<a href=&quot;https://doi.org/10.4330/wjc.v15.i8.375&quot;>10.4330/wjc.v15.i8.375</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37771340/&quot;>https://pubmed.ncbi.nlm.nih.gov/37771340</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end B01AC22;
